Devin Schoen

Devin Schoen

Auto-generated profile, based on publicly available information

Devin Schoen

Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA; UCSF-UC Berkeley Joint PhD Program in Bioengineering, Berkeley, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Science Immunology
Verified
Journal Article
Open access
TBTimothy A Bates
Timothy A Bates
SMSavannah K. McBride
Savannah K. McBride
HLHans C. Leier
Hans C. Leier
GGGaelen Guzman
Gaelen Guzman
ZLZoe Lyski
Zoe Lyski
FTFikadu Tafesse
Fikadu Tafesse
Current coronavirus disease 2019 (COVID-19) vaccines effectively reduce overall morbidity and mortality and are vitally important to controlling the pandemic. Individuals who previously recovered from COVID-19 have enhanced immune responses after vaccination (hybrid immunity) compared with their naïve-vaccinated peers; however, the effects of post-vaccination breakthrough infections on humoral immune response remain to be determined. Here, we measure neutralizing antibody responses from 104 vaccinated individuals, including those with breakthrough infections, hybrid immunity, and no infection history. We find that human immune sera after breakthrough infection and vaccination after natural infection broadly neutralize SARS-CoV-2 (severe acute respiratory coronavirus 2) variants to a similar degree. Although age negatively correlates with antibody response after vaccination alone, no correlation with age was found in breakthrough or hybrid immune groups. Together, our data suggest that the additional antigen exposure from natural infection substantially boosts the quantity, quality, and breadth of humoral immune response regardless of whether it occurs before or after vaccination.

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDevin Schoen
Devin Schoen
SDSkyler Deutsch
Skyler Deutsch
JMJuhi Mehta
Juhi Mehta
SWSarah Wang
Sarah Wang
JKJohn Kornak
John Kornak
MMMelanie A. Morrison
Melanie A. Morrison
While deep brain stimulation (DBS) remains an effective therapy for Parkinson’s disease (PD), sources of variance in patient outcomes are still not fully understood, underscoring a need for better prognostic criteria. Here, we leveraged routinely collected T1-weighted (T1-w) magnetic resonance imaging (MRI) data to derive patient-specific measures of brain structure and evaluate their usefulness in predicting changes in PD medications in response to DBS. Preoperative T1-w MRI data from 231 patients with PD were used to extract regional measures of fractal dimension (FD), sensitive to the structural complexities of cortical and subcortical brain. FD was validated as a biomarker of PD progression through comparison of patients with PD and healthy controls (HCs). This analysis revealed significant group differences in FD across nine brain regions, including frontal, occipital, insular, and basal ganglia areas, which supports its utility as a marker of PD. We evaluated the impact of adding imaging features (FD) to a clinical model that included demographics and clinical parameters (age, sex, total number and location of DBS electrodes), and preoperative motor response to levodopa. This model aimed to explain variance and predict changes in medication following DBS. Regression analysis revealed that inclusion of the FD of distributed brain areas correlated with post-DBS reductions in medication burden, explaining an additional 13.6% of outcome variance (R2 = 0.388) compared to clinical features alone (R2 = 0.252). Hypergraph-based classification learning tasks achieved an area under the receiver operating characteristic curve of 0.64 when predicting with clinical features alone, versus 0.76 when combining clinical and imaging features. These findings demonstrate that PD effects on brain morphology linked to disease progression influence DBS outcomes. The work also highlights FD as a potentially useful imaging biomarker to enhance DBS candidate selection criteria for optimized treatment planning.

23 September 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
DSDevin Schoen
Devin Schoen
PSPhilip Shih
Philip Shih
LWLucia West
Lucia West
SDSkyler Deutsch
Skyler Deutsch
JMJuhi Mehta
Juhi Mehta
MMMelanie A. Morrison
Melanie A. Morrison
Diffusion-based tractography has been used to predict deep brain stimulation (DBS) outcomes in Parkinson's disease (PD), but the predictive value of fractional anisotropy (FA) maps, which can be generated with far less computation, remains underexplored. We retrospectively analyzed preoperative diffusion MRI from 143 patients with PD who underwent DBS between 2013 and 2023. Whole-brain and tract-specific FA measures were extracted and evaluated against the pre-to-postoperative change in levodopa equivalent daily dose (ΔLEDD). Nested regression models compared clinical predictors alone with models that added whole-brain FA or stability-selected tract-specific FA. Tract-specific FA explained an additional 2.3-3.4% of ΔLEDD variance (p = 0.038), whereas whole-brain FA did not (p = 0.497); effects were in the same direction, though smaller and no longer significant, after adjustment for gold-standard motor response to dopaminergic medications. The uncinate fasciculus and cingulum of the cingulate gyrus were most consistently selected. Preoperative tract-specific FA may complement established clinical predictors of DBS outcome in PD.

12 December 2024 in Research Square
Verified
Preprint
Open access
PDF file
DSDevin Schoen
Devin Schoen
SDSkyler Deutsch
Skyler Deutsch
JMJuhi Mehta
Juhi Mehta
SWSarah Wang
Sarah Wang
JKJohn Kornak
John Kornak
MMMelanie Morrison
Melanie Morrison
While deep brain stimulation (DBS) remains an effective therapy for Parkinson’s disease (PD), sources of variance in patient outcomes are still not fully understood, underscoring a need for better prognostic criteria. Here we leveraged routinely collected T1-weighted (T1-w) magnetic resonance imaging (MRI) data to derive patient-specific measures of brain structure and evaluate their usefulness in predicting changes in PD medications in response to DBS. Preoperative T1-w MRI data from 231 patients with PD were used to extract regional measures of fractal dimension (FD), sensitive to the structural complexities of cortical and subcortical areas. FD was validated as a biomarker of Parkinson's disease (PD) progression through comparison of patients with PD and healthy controls (HCs). This analysis revealed significant group differences in FD across nine brain regions which supports its utility as a marker of PD. We evaluated the impact of adding imaging features (FD) to a clinical model that included demographics and clinical parameters—age, sex, total number and location of DBS electrodes, and preoperative motor response to levodopa. This model aimed to explain variance and predict changes in medication following DBS. Regression analysis revealed that inclusion of the FD of distributed brain areas correlated with post-DBS reductions in medication burden, explaining an additional 13.6% of outcome variance (R2=0.388) compared to clinical features alone (R2=0.252). Hypergraph-based classification learning tasks achieved an area under the receiver operating characteristic curve of 0.64 when predicting with clinical features alone, versus 0.76 when combining clinical and imaging features. These findings demonstrate that PD effects on brain morphology linked to disease progression influence DBS outcomes. The work also highlights FD as a potentially useful imaging biomarker to enhance DBS candidate selection criteria for optimized treatment planning.